Arcutis Biotherapeutics (ARQT) announced the commercial launch of ZORYVE cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in the United States. ZORYVE cream 0.05% will be available in pharmacies this week. The product is being reviewed by commercial pharmacy benefit managers and other plans to enable similar coverage as the entire ZORYVE portfolio.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
- Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
- Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating